{"title":"Renal outcomes in myeloma associated acute kidney injury; a single centre experience","authors":"Shivendra Singh, H. Sreenidhi","doi":"10.34172/jrip.2022.32020","DOIUrl":null,"url":null,"abstract":"Introduction: At initial diagnosis of multiple myeloma (MM) 30% to 40% of patients has renal impairment and acute kidney injury (AKI) being most common renal presentation. Poor renal outcome is associated with poor overall survival of patients. Objectives: The present study was conducted to determine renal outcome in patients with newly diagnosed MM presenting with AKI. Patients and Methods: A prospective observational study was carried out from March 2016 to March 2021. We included newly diagnosed myeloma patients presenting with AKI. Diagnosis and staging of AKI was conducted by kidney disease improving global outcomes (KDIGO) guidelines. Diagnosis of MM was performed by International Myeloma Working Group (IMWG) criteria. Complete renal response was defined as estimated glomerular filtration rate (eGFR) of ≥60 mL/min. Statistical analysis was done using SPSS Statistics software version 28. Results: Total number of patients were 48 male, female was 32.16, median age was 69 years. With a median follow-up of 9 weeks 30 patients (62.5%) had complete renal response, 10 patients (20.8%) expired and 8 patients (16.6%) were dialysis dependent. On comparing patients with and without complete renal response, significant variables were serum creatinine (P<0.001), serum calcium (P<0.001), oliguria at presentation (P<0.001), RRT requirement (P<0.001), AKI stage Ⅲ (P<0.001) and light chain myeloma(P<0.001). On Kaplan Meier analysis oliguria at presentation (P<0.001), renal replacement therapy (RRT) requirement (P<0.001), AKI stage Ⅲ (P<0.001) and light chain myeloma (P<0.001) were significantly associated with poor renal outcomes. Conclusion: In patients with newly diagnosed MM presenting with AKI renal recovery is 62.5%. Factors associated with poor renal recovery are higher serum creatinine, oliguria, RRT requirement, AKI stage Ⅲ and light chain myeloma.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Injury Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2022.32020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: At initial diagnosis of multiple myeloma (MM) 30% to 40% of patients has renal impairment and acute kidney injury (AKI) being most common renal presentation. Poor renal outcome is associated with poor overall survival of patients. Objectives: The present study was conducted to determine renal outcome in patients with newly diagnosed MM presenting with AKI. Patients and Methods: A prospective observational study was carried out from March 2016 to March 2021. We included newly diagnosed myeloma patients presenting with AKI. Diagnosis and staging of AKI was conducted by kidney disease improving global outcomes (KDIGO) guidelines. Diagnosis of MM was performed by International Myeloma Working Group (IMWG) criteria. Complete renal response was defined as estimated glomerular filtration rate (eGFR) of ≥60 mL/min. Statistical analysis was done using SPSS Statistics software version 28. Results: Total number of patients were 48 male, female was 32.16, median age was 69 years. With a median follow-up of 9 weeks 30 patients (62.5%) had complete renal response, 10 patients (20.8%) expired and 8 patients (16.6%) were dialysis dependent. On comparing patients with and without complete renal response, significant variables were serum creatinine (P<0.001), serum calcium (P<0.001), oliguria at presentation (P<0.001), RRT requirement (P<0.001), AKI stage Ⅲ (P<0.001) and light chain myeloma(P<0.001). On Kaplan Meier analysis oliguria at presentation (P<0.001), renal replacement therapy (RRT) requirement (P<0.001), AKI stage Ⅲ (P<0.001) and light chain myeloma (P<0.001) were significantly associated with poor renal outcomes. Conclusion: In patients with newly diagnosed MM presenting with AKI renal recovery is 62.5%. Factors associated with poor renal recovery are higher serum creatinine, oliguria, RRT requirement, AKI stage Ⅲ and light chain myeloma.
期刊介绍:
The Journal of Renal Injury Prevention (JRIP) is a quarterly peer-reviewed international journal devoted to the promotion of early diagnosis and prevention of renal diseases. It publishes in March, June, September and December of each year. It has pursued this aim through publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypothesis, case reports, epidemiology and prevention, news and views and renal biopsy teaching point. In this journal, particular emphasis is given to research, both experimental and clinical, aimed at protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between renal pathologists/nephropathologists and nephrologists. In addition, JRIP welcomes basic biomedical as well as pharmaceutical scientific research applied to clinical nephrology. Futuristic conceptual hypothesis that integrate various fields of acute kidney injury and renal tubular cell protection are encouraged to be submitted.